New Model for Predicting Cancer Outcomes

Predicting the long-term outcomes and risk of progression in patients with cancer is an important component of care that can drive treatment strategies. Unfortunately, current risk prediction models are lacking and focus primarily on pretreatment factors such as tumor phenotype and patient characteristics, which are not always indicative of long-term outcome. The need for improved […]

Read More

Immunotherapy-saves-world-prIME-LINES

Encorafenib Plus Cetuximab and Binimetinib Improves OS in BRAF Mutant CRC

Approximately 10% to 15% of patients with metastatic colorectal cancer (mCRC) carry BRAF V600E mutations, which are associated with a poor prognosis and limited treatment options. Treatment with BRAF inhibitors has historically been ineffective due to multiple feedback mechanisms present in the MAP kinase pathway, leading to resistance. In other tumor types, combination of BRAF […]

Read More

fda-approvals-june-2019

FDA Issues Four Oncology/Hematology Approvals in June

Two New Indications for Pembrolizumab. The FDA extended the indication of the PD-1 inhibitor pembrolizumab (Keytruda®, Merck) to include its use as a first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and for the treatment of patients with metastatic small cell lung cancer (SCLC) who have disease progression after at […]

Read More

Daratumumab-VTd Combo, a New Option For Transplant Eligible Myeloma

The majority of patients with newly diagnosed multiple myeloma (NDMM) are treated with induction therapy followed by autologous stem cell transplant (ASCT) and consolidation therapy. The combination of bortezomib, thalidomide, and dexamethasone (VTd) is one of the standard induction/consolidation regimens. Daratumumab, a CD38-targeting antibody, is effective as monotherapy and in combinations in relapsed or refractory […]

Read More

Lenalidomide Can Prevent Development of Symptomatic Multiple Myeloma

Smoldering multiple myeloma (SMM) is a heterogeneous disease. While observation is often sufficient for patients with low-risk disease, those with high-risk characteristics are more likely to develop symptomatic multiple myeloma (MM) and have poor outcomes. Early intervention in patients with high-risk disease may be an effective strategy to improve outcomes in this population. This was […]

Read More

Promising Targeted Therapies for Hard-to-Treat Molecularly Driven NSCLC

Targeted therapy is currently the preferred treatment approach for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR, ALK, ROS1, BRAF, and NTRK alterations, while immune checkpoint inhibitors with or without chemotherapy are the standard of care for patients without these mutations. In recent years, new actionable targets in NSCLC have been uncovered and […]

Read More